The OSTEOproSPINE consortium came together to provide a long-term solution for the treatment of degenerative spine disorder through a personalised bone implant.
Utilising the research results of the former H2020 project OSTEOGROW, OSTEOproSPINE has been setting new pathways for the innovation in spinal surgery for the benefits of millions of patients worldwide.
In OSTEOproSPINE we will use the patient’s peripheral blood and translate it to extra skeletal bone, based on the research results of our previous project OSTEOGROW.
By combining the protein with allograft we will ensure a quicker bone generation and avoid a second surgical procedure for the patients to harvest bone from the pelvis.Prof. Slobodan Vukicevic, OSTEOproSPINE coordinatorUniversity of Zagreb School of Medicine
Millions of people worldwide suffer from chronic lumbar back pain, which is the second most common medical condition after a cold. Because of its chronic nature, lumbar back pain constitutes an enormous burden for patients and leads to very high costs for healthcare systems.
Mostly caused by degenerative spine disorders, approximately 1.5 million patients in the EU alone need a surgical intervention to treat lumbar back pain.